Skip to content

Precigen PGEN Investment and other (expense) income, net

Investment and other (expense) income, net at other companies

Erie Indemnity Company logo
Erie Indemnity CompanyERIE
$22.12M+13.2%
Diebold Nixdorf logo
Diebold NixdorfDBD
$2.9M+93.3%
Teradata logo
TeradataTDC
$3M0.0%
Bel Fuse logo
Bel FuseBELFB
$258.75K-78.2%
Cloudflare, Inc. logo
Cloudflare, Inc.NET
$40.17M+87.7%
Nine Energy Service logo
Nine Energy ServiceNINE
$1K-99.3%

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.93B+213%

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeNonoperating.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's investment and other (expense) income, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's investment and other (expense) income, net?
Precigen (PGEN) reported investment and other (expense) income, net of $683K in Q1 2026.
How has Precigen's investment and other (expense) income, net changed year-over-year?
Precigen's investment and other (expense) income, net decreased by 25.6% year-over-year, from $918K to $683K.
What does investment and other (expense) income, net mean?
This metric represents the net financial impact of non-operating investment activities, including interest income, interest expense, and changes in the fair value of financial instruments such as warrant liabilities. It captures gains or losses derived from sources outside of the company's core synthetic biology operations. Investors monitor this to assess the volatility and impact of non-core financial items on the company's overall bottom line.